Argentina has relaxed its regulations concerning pharmaceutical patents, removing a series of restrictions on foreign products that have been in place since 2012, thereby facilitating imports. The alteration was executed in accordance with a pact established with the United States government. On Wednesday, the Argentine government rescinded a 2012 resolution that outlined the procedures for the analysis and approval of pharmaceutical patents. The National Institute of Intellectual Property will assume responsibility for processing patent requests, conducting an individual analysis of each case, a practice it previously engaged in prior to the resolution in question. The alteration signifies the removal of limitations on specific categories of pharmaceutical and biotechnological products, which until now could exclusively be patented by companies based in Argentina.
The removal of those restrictions had been a protracted demand from the United States. The international pharmaceutical industry has expressed concerns that the regulation facilitates the emergence of copycat products that are patented in Argentina. A segment of the national pharmaceutical sector supported the regulation, arguing that it facilitated the development of their own generic versions of specific products. This, in turn, enhanced the national industry’s competitiveness and offered more affordable alternatives to consumers. However, the elimination of the restrictions will not have a retroactive effect, indicating that generic medications currently available in the Argentine market will remain on offer. Deregulation minister Federico Sturzenegger, who was behind the decision, stated on X that it signifies “a transcendental improvement regarding intellectual property” in Argentina.
He stated that the 2012 resolution, enacted under the administration of Cristina Kirchner, “had made it very hard (if not impossible) to obtain a medical patent in Argentina,” which not only “violated the right to property” but also “delayed the arrival of innovating therapies to the country.” Sturzenegger articulated that the decision aligns Argentina with global benchmarks regarding intellectual property, asserting that, in return for this action, the U.S. will “open its entire domestic market to our pharmaceutical industry.” The American Chamber of Commerce in Argentina (AmCham) expressed approval of the decision, stating it will “boost innovation in healthcare, eliminating restrictions that for years limited pharmaceutical patents.”
“Argentina is creating conditions to attract investment, developing knowledge and competing globally again,” stated AmCham in a post on X. “When predictability, investment and innovation connect, the result is clear: a more competitive economy, and a more robust health system.” The Industrial Chamber of Argentine Pharmaceutical Laboratories (CILFA, by its Spanish initials) expressed confidence in the National Institute of Intellectual Property’s “competence and technical capability” to analyze patent requests “rigorously and on a scientific basis, granting patents for genuine pharmaceutical innovations.” The chamber stated “The issue transcends the private interests of the companies represented by CILFA and fundamentally impacts the public interest in health and access to medicines.”